This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.

This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.

The present disclosure relates to implantable constructs designed to deliver antigenic therapeutic reagents to a subject while providing protection from host immune responses. In certain aspects, the constructs are designed to degrade over time or upon a particular signal, thereby providing control of the length of time the therapeutic agent is delivered to the subject.

Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.

The present disclosure relates to modified forms, or muteins, of IL-10, as well as variants thereof, which display improved features as compared to wild-type IL-10. The present invention further relates to the use of such modified forms, or muteins, of IL-10, as well as variants thereof in methods, including therapeutic methods.

The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1:

(first monomer subunit)-LINKER-(second monomer subunit)   Formula 1 wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.

Macromolecule compositions and related methods that effect targeted delivery of therapeutic agents to effector targets in a desired cell, tissue and/or organ of interest while minimizing or avoiding undesirable delivery to other cells, tissues or organs are provided. Compositions and methods related to macromolecules, such as an ANDbody™, that include an effector target binding domain specific for an effector target, and an address binding domain specific for an address target are described.

Aspects of the present disclosure relate to genetically engineered organisms useful for the diagnosis and treatment of inflammatory bowel disease.

Methods of enhancing production of cytokines such as IL-10 by, for example, optimizing refolding conditions, are described. The methods provide an efficient, cost-effective means of manufacturing IL-10 on a commercial scale.

The present disclosure relates generally to compositions and methods for modulating signal transduction mediated by interleukin-10 (IL-10). In particular, the disclosure provides novel IL-10 polypeptide variants with altered binding affinity to interleukin-10 receptor subunit beta (IL-10Rβ). Also provided are compositions and methods useful for producing such IL-10 polypeptide variants, as well as methods for modulating IL-10-mediated signaling, and/or for the treatment of conditions associated with the perturbation of signal transduction mediated by IL-10.